Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02327078 | A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) | completed | Phase 1 / Phase 2 | 307 | Incyte CorporationINDUSTRY | 2 | Aug 14, 2025 | clinicaltrials |
| NCT06941818 | HS-IT101 Injection in the Treatment of Advanced Melanoma | enrolling by invitation | Phase 1 | 10 | Qingdao Sino-Cell Biomedicine Co., Ltd.INDUSTRY | 1 | Aug 14, 2025 | clinicaltrials |
| NCT07121829 | Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors | terminated | Phase 1 | 44 | Day One Biopharmaceuticals, Inc.INDUSTRY | 2 | Aug 14, 2025 | clinicaltrials |
| NCT01863108 | Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma(GeniusVac-Mel4) | completed | Phase 1 | 9 | University Hospital, GrenobleOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT02475213 | Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer | completed | Phase 1 | 146 | MacroGenicsINDUSTRY | 1 | Aug 11, 2025 | clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT03611868 | A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 230 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Aug 7, 2025 | clinicaltrials |
| NCT04217473 | TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma(TUNINTIL) | completed | Phase 1 | 17 | TILT Biotherapeutics Ltd.INDUSTRY | 2 | Aug 7, 2025 | clinicaltrials |
| NCT05222932 | Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1(AVENTIL) | active not recruiting | Phase 1 | 15 | TILT Biotherapeutics Ltd.INDUSTRY | 2 | Aug 7, 2025 | clinicaltrials |
| NCT05717140 | Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung | withdrawn | Phase 1 | 0 | Mayo ClinicOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07107178 | A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant Melanoma | not yet recruiting | Phase 1 | 58 | Biotroy TherapeuticsINDUSTRY | 0 | Aug 6, 2025 | clinicaltrials |
| NCT01239134 | Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors(TRX518-001) | completed | Phase 1 | 10 | Leap Therapeutics, Inc.INDUSTRY | 1 | Aug 3, 2025 | clinicaltrials |
| NCT03729596 | MGC018 With or Without MGA012 in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 143 | MacroGenicsINDUSTRY | 4 | Jul 31, 2025 | clinicaltrials |
| NCT05303493 | Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma | completed | Phase 1 | 45 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT04904185 | ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma | terminated | Phase 1 | 8 | Inge Marie SvaneOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT04616443 | OH2 Injection in Combination With HX008 for Melanoma. | recruiting | Phase 1 / Phase 2 | 60 | Binhui Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 24, 2025 | clinicaltrials |
| NCT06299163 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | terminated | Phase 1 | 11 | Numab Therapeutics AGINDUSTRY | 1 | Jul 23, 2025 | clinicaltrials |
| NCT05116202 | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) | completed | Phase 1 / Phase 2 | 110 | Hoffmann-La RocheINDUSTRY | 5 | Jul 18, 2025 | clinicaltrials |
| NCT04116320 | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors(AM-003) | terminated | Phase 1 | 5 | Craig L Slingluff, JrOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT07063875 | Adding IL-2 to Tebentafusp to Eradicate Cancer Progression(SILVER) | recruiting | Phase 1 / Phase 2 | 8 | St Vincent's Hospital, SydneyOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT02836548 | HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma | completed | Phase 1 / Phase 2 | 33 | The Netherlands Cancer InstituteOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT06112808 | A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin | active not recruiting | Phase 1 | 300 | BiocadINDUSTRY | 2 | Jul 8, 2025 | clinicaltrials |
| NCT02680184 | Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy | completed | Phase 1 | 199 | Regeneron PharmaceuticalsINDUSTRY | 1 | Jul 4, 2025 | clinicaltrials |
| NCT03991741 | Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors | terminated | Phase 1 | 3 | Gregory DanielsOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT05573035 | A Study to Investigate LYL845 in Adults With Solid Tumors | terminated | Phase 1 | 39 | Lyell Immunopharma, Inc.INDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT00683670 | Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma | completed | Phase 1 | 17 | University of PennsylvaniaOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT07040436 | Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1(REVERT) | not yet recruiting | Phase 1 / Phase 2 | 41 | Oncodesign Precision MedicineINDUSTRY | 0 | Jun 27, 2025 | clinicaltrials |
| NCT05432193 | FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER) | terminated | Phase 1 | 20 | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and CompanyINDUSTRY | 2 | Jun 25, 2025 | clinicaltrials |
| NCT05180799 | A Phase 1/2 Study of BA3071 in Patients With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 320 | BioAtla, Inc.INDUSTRY | 2 | Jun 15, 2025 | clinicaltrials |
| NCT01351103 | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | completed | Phase 1 | 185 | Novartis PharmaceuticalsINDUSTRY | 7 | Jun 13, 2025 | clinicaltrials |
| NCT03325101 | Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma | terminated | Phase 1 / Phase 2 | 7 | Mayo ClinicOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT02836795 | Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors | completed | Phase 1 | 35 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT06596915 | Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 167 | Shandong Boan Biotechnology Co., LtdINDUSTRY | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06190249 | Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma | withdrawn | Phase 1 | 0 | James Isaacs, MDOTHER | 0 | Jun 5, 2025 | clinicaltrials |
| NCT02259231 | RTA 408 Capsules in Patients With Melanoma - REVEAL | completed | Phase 1 / Phase 2 | 41 | BiogenINDUSTRY | 1 | Jun 4, 2025 | clinicaltrials |
| NCT02419495 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | terminated | Phase 1 | 221 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT04068896 | Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy | completed | Phase 1 / Phase 2 | 89 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | May 29, 2025 | clinicaltrials |
| NCT06208124 | A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors | completed | Phase 1 / Phase 2 | 30 | Immuneering CorporationINDUSTRY | 1 | May 28, 2025 | clinicaltrials |
| NCT05970497 | A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 240 | Krystal Biotech, Inc.INDUSTRY | 1 | May 18, 2025 | clinicaltrials |
| NCT01703507 | Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma | completed | Phase 1 | 17 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT02318771 | Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer | completed | Phase 1 | 41 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT03922880 | Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma | completed | Phase 1 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT05144698 | RAPA-201 Therapy of Solid Tumors | recruiting | Phase 1 / Phase 2 | 37 | Rapa Therapeutics LLCINDUSTRY | 1 | May 14, 2025 | clinicaltrials |
| NCT00386906 | Sentinel Lymph Node (SLN) Biopsy for Conjunctival/Eyelid Melanoma | completed | Phase 1 | 38 | M.D. Anderson Cancer CenterOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT00405405 | Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer | completed | Phase 1 | 13 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT02145910 | Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases | withdrawn | Phase 1 | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 0 | May 2, 2025 | clinicaltrials |
| NCT04301011 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors(RAPTOR) | terminated | Phase 1 | 27 | Turnstone Biologics, Corp.INDUSTRY | 3 | Apr 23, 2025 | clinicaltrials |
| NCT04706962 | TH1902 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 70 | TheratechnologiesINDUSTRY | 2 | Apr 15, 2025 | clinicaltrials |
| NCT02974725 | A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma | terminated | Phase 1 | 241 | Novartis PharmaceuticalsINDUSTRY | 11 | Apr 13, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Aug 14, 2025source: clinicaltrials